Cardiol Therapeutics Inc. (CRDL) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 0.99 |
| Open | 1 |
| Day High | 1.03 |
| Day Low | 0.96 |
| 52-Week High | 1.71 |
| 52-Week Low | 0.88 |
| Volume | 361,633 |
| Average Volume | 470,438 |
| Market Cap | 116.42M |
| PE | -3.59 |
| EPS | -0.28 |
| Moving Average 50 Days | 1.17 |
| Moving Average 200 Days | 1.11 |
| Change | 0.02 |
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Newsfile
Feb 25, 2026 12:27 PM GMT
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Newsfile
Feb 10, 2026 12:27 PM GMT
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Newsfile
Jan 23, 2026 2:16 PM GMT
Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic